Form 4 for SLS SELLAS Life Sciences Group, Inc.
Accepted 2024-01-25 00:00:00 ET · period of report 2024-01-22 · accession 0001104659-24-006379 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-25 | 2024-01-22 | SLS | Burns John Thomas | CFO | A - Grant | $0.00 | +47.0K | 101.9K | +86% | $0 |
| D | 2024-01-25 | 2024-01-22 | SLS | Burns John Thomas | CFO | A - Grant | $0.00 | +75.0K | 75.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-22 | A | A | 47,000 | $0.00 | 101,927 | D | — | — | (F1) The Reporting Person received an award of 47,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-01-22 | A | A | 75,000 | $0.00 | 75,000 | D | $0.52 · — to 2034-01-22 | 75,000 Common Stock | (F2) One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |